

DAFTAR PUSTAKA

1. Mackenzie G. The definition and classification of pneumonia. *Pneumonia* (Nathan). 2016;8:14. Published 2016 Aug 22. doi:10.1186/s41479-016-0012-z
2. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. *Pneumonia*. 2020;12(1):11. doi:10.1186/s41479-020-00074-3
3. Kementrian Kesehatan RI. 2019. Laporan Nasional Riskesdas 2018, Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan.
4. Margolis P, Gadomski A. 2015. Does This Infant Have Pneumonia? 28;279(4):308-13. doi: 10.1001/jama.279.4.308.
5. Mani CS. Acute Pneumonia and Its Complications. *Principles and Practice of Pediatric Infectious Diseases*. 2018;238-249.e4. doi:10.1016/B978-0-323-40181-4.00034-7
6. Cilloniz C, Martin-Loeches I, Garcia-Vidal C, San Jose A, Torres A. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. *IJMS*. 2016;17(12):2120. doi:10.3390/ijms17122120
7. Knight GM, Dyakova E, Mookerjee S, et al. Fast and Expensive (PCR) or Cheap and Slow (Culture)? A Mathematical Modelling Study to Explore Screening for Carbapenem Resistance in UK Hospitals. *BMC Med*. 2018;16(1):141. doi:10.1186/s12916-018-1117-4
8. Meyer Sauter PM. Challenges and Progress Toward Determining Pneumonia Etiology. *Clinical Infectious Diseases*. 2020;71(3):514-516. doi:10.1093/cid/ciz879
9. Jiang R, Han B, Dou C, Zhou F, Cao B, Li X. Analysis of antibiotic usage for viral community-acquired pneumonia in adults. *Front Med*. 2021;15(1):139-143. doi:10.1007/s11684-019-0736-2
10. Provenzani A, Hospodar AR, Meyer AL, et al. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents. *Int J Clin Pharm*. 2020;42(4):1016-1025. doi:10.1007/s11096-020-01089-y



11. Cillóniz C, Torres A, Niederman MS. Management of pneumonia in critically ill patients. *BMJ*. Published online December 6, 2021:e065871. doi:10.1136/bmj-2021-065871
12. Smidowicz A, Regula J. Effect of nutritional status and dietary patterns on human serum C-reactive protein and interleukin-6 concentrations. *Adv Nutr*. 2015;6(6):738-747. Published 2015 Nov 13. doi:10.3945/an.115.009415
13. Tang Y, Fung E, Xu A, Lan HY. C-reactive protein and ageing. *Clin Exp Pharmacol Physiol*. 2017;44:9-14. doi:10.1111/1440-1681.12758
14. Koozi H, Lengquist M, Frigyesi A. C-reactive protein as a prognostic factor in intensive care admissions for sepsis: A Swedish multicenter study. *Journal of Critical Care*. 2020;56:73-79. doi:10.1016/j.jcrc.2019.12.009
15. Lavery LA, Ahn J, Ryan EC, et al. What are the Optimal Cutoff Values for ESR and CRP to Diagnose Osteomyelitis in Patients with Diabetes-related Foot Infections? *Clin Orthop Relat Res*. 2019;477(7):1594-1602.
16. Vuong NL, Le Duyen HT, Lam PK, et al. C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study. *BMC Med*. 2020;18(1):35. doi:10.1186/s12916-020-1496-1
17. Rachina S, Bobylev A, Lazarev P, et al. Biomarker Value in the Diagnosis of Community-Acquired Pneumonia with Concomitant Chronic Heart Failure. *JCM*. 2021;10(19):4570. doi:10.3390/jcm10194570
18. Azzini AM, Dorizzi RM, Sette P, et al. A 2020 review on the role of procalcitonin in different clinical settings: an update conducted with the tools of the Evidence Based Laboratory Medicine. *Ann Transl Med*. 2020;8(9):610-610. doi:10.21037/atm-20-1855
19. Meisner M. Update on Procalcitonin Measurements. *Ann Lab Med*. 2014;34(4):263-273. doi:10.3343/alm.2014.34.4.263
20. Kamat IS, Ramachandran V, Eswaran H, Guffey D, Musher DM. Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis. *Clinical Infectious Diseases*. 2020;70(3):538-542. doi:10.1093/cid/ciz545
21. Kumar V, Abbas A, Aster JC, editors. Robbins basic pathology e-book. Elsevier Health Sciences; 2017 Mar 8.



22. Haywood M. Interpreting the full blood count. *InnovAiT*. 2022;15(3):131-137. doi:10.1177/1755738021106577323.
23. Buonacera A, Stancanelli B, Colaci M, Malatino L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. *IJMS*. 2022;23(7):3636. doi:10.3390/ijms23073636
24. Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. *BLL*. 2021;122(07):474-488. doi:10.4149/BLL_2021_078
25. InformedHealth.org [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2006-. Pneumonia: Overview. 2018 Aug 9. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK525774/>
26. Kabra SK, Lodha R, Pandey RM. Antibiotics for community-acquired pneumonia in children. *Cochrane Database Syst Rev*. 2010;(3):CD004874. Published 2010 Mar 17. doi:10.1002/14651858.CD004874.pub3
27. Kharel S, Bist A, Mishra SK. Ventilator-associated pneumonia among ICU patients in WHO Southeast Asian region: A systematic review. *PLoS One*. 2021;16(3):e0247832. Published 2021 Mar 9. doi:10.1371/journal.pone.0247832
28. Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. *Nat Rev Dis Primers*. 2021;7(1):25. doi:10.1038/s41572-021-00259-0
29. Qin T, Zhou H, Ren H, et al. Incidence, aetiology, and enviromental risk factors of community-acquired pneumonia requiring hospitalization in China: a 3-year, prospective, age-stratified, multi-centre case-control study. *Open Forum Infectious Diseases*. Published online October 6, 2021:ofab499. doi:10.1093/ofid/ofab499
30. Patterson CM, Loebinger MR. Community acquired pneumonia: assessment and treatment. *Clin Med*. 2012;12(3):283-286. doi:10.7861/clinmedicine.12-3-283
31. Farida H, Gasem MH, Suryanto A, et al. Viruses and Gram-negative bacilli dominate the etiology of community-acquired pneumonia in Indonesia, a cohort study. *International Journal of Infectious Diseases*. 2015;38:101-107. doi:10.1016/j.ijid.2015.07.023
32. Iskanda D, Farida H, Triasih R, et al. Epidemiology of community-acquired pneumonia among hospitalised children in Indonesia: a multicentre,



- prospective study. *BMJ Open*. 2022;12(6):e057957. doi:10.1136/bmjopen-2021-057957
33. Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. *Nat Rev Dis Primers*. 2021;7(1):25. Published 2021 Apr 8. doi:10.1038/s41572-021-00259-0
 34. Weir I, Silvestri L, van Saene HK. Etiology and pathophysiology of hospital-acquired pneumonia. In: *Hospital-Acquired Pneumonia*. Future Medicine Ltd; 2013:18-30. doi:10.2217/ebo.12.226
 35. Jain V, Vashisht R, Yilmaz G, et al. Pneumonia Pathology. [Updated 2022 Aug 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK526116/>
 36. Htun TP, Sun Y, Chua HL, Pang J. Clinical features for diagnosis of pneumonia among adults in primary care setting: A systematic and meta-review. *Sci Rep*. 2019;9(1):7600. Published 2019 May 20. doi:10.1038/s41598-019-44145-y
 37. Moore M, Stuart B, Little P, et al. Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study. *Eur Respir J*. 2017;50(5):1700434. doi:10.1183/13993003.00434-2017
 38. Takada T, Yamamoto Y, Terada K, et al. Diagnostic utility of appetite loss in addition to existing prediction models for community-acquired pneumonia in the elderly: a prospective diagnostic study in acute care hospitals in Japan. *BMJ Open*. 2017;7(11):e019155. Published 2017 Nov 8. doi:10.1136/bmjopen-2017-019155
 39. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. *Thorax*. 2009;64 Suppl 3:iii1-iii55. doi:10.1136/thx.2009.121434
 40. Bradley J, Sbaih N, Chandler TR, Furmanek S, Ramirez JA, Cavallazzi R. Pneumonia Severity Index and CURB-65 Score Are Good Predictors of Mortality in Hospitalized Patients With SARS-CoV-2 Community-Acquired Pneumonia. *Chest*. 2022;161(4):927-936. doi:10.1016/j.chest.2021.10.031
 - halmers JD, Singanayagam A, Akram AR, et al. Severity assessment ols for predicting mortality in hospitalised patients with community-



- acquired pneumonia. Systematic review and meta-analysis. *Thorax*. 2010;65(10):878-883. doi:10.1136/thx.2009.133280
42. Fally M, Von Plessen C, Anhøj J, et al. Improved treatment of community-acquired pneumonia through tailored interventions: Results from a controlled, multicentre quality improvement project. Gupta V, ed. *PLoS ONE*. 2020;15(6):e0234308. doi:10.1371/journal.pone.0234308
 43. Olson G, Davis AM. Diagnosis and Treatment of Adults With Community-Acquired Pneumonia. *JAMA*. 2020;323(9):885. doi:10.1001/jama.2019.21118
 44. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage *Pseudomonas aeruginosa* infections. *DIC*. 2018;7:1-18. doi:10.7573/dic.212527
 45. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in Methicillin-Resistant *Staphylococcus aureus* Nosocomial Pneumonia: A Randomized, Controlled Study. *Clinical Infectious Diseases*. 2012;54(5):621-629. doi:10.1093/cid/cir895
 46. Aliyu B, Raji YE, Chee HY, Wong MY, Sekawi ZB. Systematic review and meta-analysis of the efficacy and safety of oseltamivir (Tamiflu) in the treatment of Coronavirus Disease 2019 (COVID-19). Abd El-Aty AM, ed. *PLoS ONE*. 2022;17(12):e0277206. doi:10.1371/journal.pone.0277206
 47. Huang M, Cai S, Su J. The Pathogenesis of Sepsis and Potential Therapeutic Targets. *IJMS*. 2019;20(21):5376. doi:10.3390/ijms20215376
 48. Zhu G, Xu Y, Cen X, Nandakumar KS, Liu S, Cheng K. Targeting pattern-recognition receptors to discover new small molecule immune modulators. *European Journal of Medicinal Chemistry*. 2018;144:82-92. doi:10.1016/j.ejmech.2017.12.026
 49. Morgenthaler NG, Struck J, Chancerelle Y, et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection. *Horm Metab Res*. 2003;35(5):290-295. doi:10.1055/s-2003-41304
 50. Paudel R, Dogra P, Montgomery-Yates AA, Coz Yataco A. Procalcitonin: A promising tool or just another overhyped test? *Int J Med Sci*. 2020;17(3):332-337. doi:10.7150/ijms.39367



Iriyama Y, Nomura Y, Tokumitsu Y. Calcitonin gene expression induced by lipopolysaccharide in the rat pituitary. *American Journal of Physiology*

- Endocrinology and Metabolism*. 2002;282(6):E1380-E1384. doi:10.1152/ajpendo.00453.2001
52. Vikse J, Henry BM, Roy J, Ramakrishnan PK, Tomaszewski KA, Walocha JA. The role of serum procalcitonin in the diagnosis of bacterial meningitis in adults: a systematic review and meta-analysis. *International Journal of Infectious Diseases*. 2015;38:68-76. doi:10.1016/j.ijid.2015.07.011
 53. Riedel S, Melendez JH, An AT, Rosenbaum JE, Zenilman JM. Procalcitonin as a Marker for the Detection of Bacteremia and Sepsis in the Emergency Department. *American Journal of Clinical Pathology*. 2011;135(2):182-189. doi:10.1309/AJCP1MFYINQLECV2
 54. De Jong E, Van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *The Lancet Infectious Diseases*. 2016;16(7):819-827. doi:10.1016/S1473-3099(16)00053-0
 55. Schuetz P, Wirz Y, Mueller B. Procalcitonin Testing to Guide Antibiotic Therapy in Acute Upper and Lower Respiratory Tract Infections. *JAMA*. 2018;319(9):925. doi:10.1001/jama.2018.0852
 56. Yoon YK, Kim MJ, Yang KS, Ham SY. The role of serum procalcitonin in the differential diagnosis of pneumonia from pulmonary edema among the patients with pulmonary infiltrates on chest radiography. *Medicine*. 2018;97(47):e13348.
 57. Zeng F, Huang Y, Guo Y, et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. *International Journal of Infectious Diseases*. 2020;96:467-474. doi:10.1016/j.ijid.2020.05.055
 58. Mokline A, Garsallah L, Rahmani I, et al. Procalcitonin: a diagnostic and prognostic biomarker of sepsis in burned patients. *Ann Burns Fire Disasters*. 2015;28(2):116-120.
 59. Marnell L, Mold C, Du Clos TW. C-reactive protein: Ligands, receptors and role in inflammation. *Clinical Immunology*. 2005;117(2):104-111. doi:10.1016/j.clim.2005.08.004
 60. Kawanami D, Maemura K, Takeda N, et al. C-reactive protein induces CAM-1 gene expression through NF- κ B activation in vascular endothelial



- cells. *Atherosclerosis*. 2006;185(1):39-46. doi:10.1016/j.atherosclerosis.2005.01.057
61. Kong DH, Kim Y, Kim M, Jang J, Lee S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. *IJMS*. 2018;19(4):1057. doi:10.3390/ijms19041057
 62. Pourhassan M, Cederholm T, Trampisch U, Volkert D, Wirth R. Inflammation as a diagnostic criterion in the GLIM definition of malnutrition—what CRP-threshold relates to reduced food intake in older patients with acute disease? *Eur J Clin Nutr*. 2022;76(3):397-400. doi:10.1038/s41430-021-00977-4
 63. Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia. *Respir Res*. 2018;19(1):193. doi:10.1186/s12931-018-0877-x
 64. Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil-to-lymphocyte ratio and mortality in the United States general population. *Sci Rep*. 2021;11(1):464. doi:10.1038/s41598-020-79431-7
 65. Mortaz E, Alipoor SD, Adcock IM, Mumby S, Koenderman L. Update on Neutrophil Function in Severe Inflammation. *Front Immunol*. 2018;9:2171. Published 2018 Oct 2. doi:10.3389/fimmu.2018.02171
 66. *Management and Prognosis of Community-Acquired Pneumonia in Adults = Behandeling En Prognose van Buiten Het Ziekenhuis Verkregen Pneumonie Bij Volwassenen*. publisher not identified; 2016.
 67. Setiawan N, Probosuseno, Riyanto BS. Neutrophil-to-Lymphocyte Ratio (N:R) sebagai faktor prognostik pasien pneumonia komunitas pada geriatri. 2020. Universitas Gadjah Mada
 68. Kuikel S, Pathak N, Poudel S, et al. Neutrophil–lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review. *Health Science Reports*. 2022;5(3). doi:10.1002/hsr2.630
 69. Lee H, Kim I, Kang BH, Um SJ. Prognostic value of serial neutrophil-to-lymphocyte ratio measurements in hospitalized community-acquired pneumonia. Zivkovic AR, ed. *PLoS ONE*. 2021;16(4):e0250067. doi:10.1371/journal.pone.0250067



70. Cataudella E, Giraffa CM, Di Marca S, et al. Neutrophil-To-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia. *J Am Geriatr Soc.* 2017;65(8):1796-1801. doi:10.1111/jgs.14894
71. Osman M, Manosuthi W, Kaewkungwal J, Silachamroon U, Mansanguan C, Kamolratanakul S, et al. Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand. *Am J Trop Med Hyg* [Internet] 2021 [cited 2023 Oct 19];104(6):2009–16. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176510/>
72. Brown JS. Community-acquired pneumonia. *Clin Med* [Internet] 2012 [cited 2023 Oct 19];12(6):538–43. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922594/>
73. Peraturan Menteri Kesehatan Republik Indonesia Nomor 25 Tahun 2016 Tentang Rencana Aksi Nasional Kesehatan Lanjut Usia Tahun 2016-2019 [Internet]. 2016;Available from: http://hukor.kemkes.go.id/uploads/produk_hukum/PMK_No._25_ttg_Rencana_Aksi_Nasional_Kesehatan_Lanjut_Usia_Tahun_2016-2019_.pdf
74. Tanigawa T, Araki S, Nakata A, Kitamura F, Yasumoto M, Sakurai S, et al. Increase in memory (CD4+CD29+ and CD4+CD45RO+) T and naive (CD4+CD45RA+) T-cell subpopulations in smokers. *Arch Environ Health* 1998;53(6):378–83.
75. Menéndez R, Ferrando D, Vallés JM, Martínez E, Perpiñá M. Initial risk class and length of hospital stay in community-acquired pneumonia. *Eur Respir J* [Internet] 2001 [cited 2023 Oct 19];18(1):151–6. Available from: <https://erj.ersjournals.com/content/18/1/151>
76. Qi X, Dong Y, Lin X, Xin W. Value of Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Red Blood Cell Distribution Width in Evaluating the Prognosis of Children with Severe Pneumonia. *Evid-Based Complement Altern Med ECAM* [Internet] 2021 [cited 2023 Oct 19];2021:1818469. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486541/>
- agerström F, Engfeldt P, Holmberg H. C-reactive protein in diagnosis of community-acquired pneumonia in adult patients in primary care. *Scand J*



- Infect Dis [Internet] 2006 [cited 2023 Oct 19];38(11–12):964–9. Available from: <https://doi.org/10.1080/00365540500388826>
78. Daga MK, Arora N, Prakash SK, Jhamb R, Kumar N, Gupta N. C-REACTIVE PROTEIN IN LOWER RESPIRATORY TRACT INFECTIONS. Lung India. 2005 Jun;22(2):41.
 79. Vázquez EG, Martínez JA, Mensa J, Sánchez F, Marcos MA, Roux A de, et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J [Internet] 2003 [cited 2023 Oct 19];21(4):702–5. Available from: <https://erj.ersjournals.com/content/21/4/702>
 80. Malek F, Gohari A, Mirmohammadkhani M, Ardiani F. Relationship Between the Serum Level of C-Reactive Protein and Severity and Outcomes of Community-Acquired Pneumonia. Arch Clin Infect Dis [Internet]. 2019 [cited 2023 Oct 24];14(2). Available from: <https://brieflands.com/articles/archcid-63893.html#abstract>
 81. Falk G, Fahey T. C-reactive protein and community-acquired pneumonia in ambulatory care: systematic review of diagnostic accuracy studies. Fam Pract. 2009 Feb 1;26(1):10–21.
 82. Manullang D, Keliat EN, Abidin A. Procalcitonin Level is Correlated with Community Pneumonia Severity. Cermin Dunia Kedokt [Internet] 2018 [cited 2023 Oct 19];45(9):647–51. Available from: <https://cdkjournal.com/index.php/cdk/article/view/718>
 83. Corica B, Tartaglia F, D'Amico T, Romiti GF, Cangemi R. Sex and gender differences in community-acquired pneumonia. Intern Emerg Med [Internet] 2022 [cited 2023 Oct 19];17(6):1575–88. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294783/>
 84. Gutiérrez F, Masia MDM, Mirete C, Soldán B, Rodríguez J, Padilla S, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006;53:166–74.
 85. Afiah, Nurul. Analysis of Neutrophil/Lymphocyte Ratio and Culture Results on Clinical Severity of Patients with CAP. Indones J Clin Pathol Med Lab [Internet] 2023 [cited 2023 Oct 19]; Available from: [tps://www.indonesianjournalofclinicalpathology.org/index.php/patologi/article/view/1987](https://www.indonesianjournalofclinicalpathology.org/index.php/patologi/article/view/1987)



86. Kuikel S, Pathak N, Poudel S, Thapa S, Bhattarai SL, Chaudhary G, et al. Neutrophil–lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review. *Health Sci Rep* [Internet] 2022 [cited 2023 Oct 19];5(3):e630. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9060320/>
87. Morris AC. Management of pneumonia in intensive care. *J Emerg Crit Care Med* [Internet] 2018 [cited 2023 Oct 19];2(0). Available from: <https://jeccm.amegroups.org/article/view/4830>
88. Li W, Ding C, Yin S. Severe pneumonia in the elderly: a multivariate analysis of risk factors. *Int J Clin Exp Med* [Internet] 2015 [cited 2023 Oct 19];8(8):12463–75. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612842/>
89. Yang T, Wan C, Wang H, Qin J, Chen L, Shen Y, et al. The prognostic and risk-stratified value of neutrophil–lymphocyte count ratio in Chinese patients with community-acquired pneumonia. *Eur J Inflamm* [Internet] 2017 [cited 2023 Oct 19];15(1):22–7. Available from: <https://doi.org/10.1177/1721727X17702150>
90. Ozbay S, Ayan M, Ozsoy O, Akman C, Karcioglu O. Diagnostic and Prognostic Roles of Procalcitonin and Other Tools in Community-Acquired Pneumonia: A Narrative Review. *Diagn Basel Switz* 2023;13(11):1869.
91. Ruopp MD, Perkins NJ, Whitcomb BW, Schisterman EF. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom J Biom Z* 2008;50(3):419–30.
92. Cataudella E, Giraffa CM, Di Marca S, Pulvirenti A, Alaimo S, Pisano M, et al. Neutrophil-To-Lymphocyte Ratio: An Emerging Marker Predicting Prognosis in Elderly Adults with Community-Acquired Pneumonia. *J Am Geriatr Soc* 2017;65(8):1796–801.
93. Le Bel J, Hausfater P, Chenevier-Gobeaux C, Blanc FX, Benjoar M, Ficko C, et al. Diagnostic accuracy of C-reactive protein and procalcitonin in suspected community-acquired pneumonia adults visiting emergency department and having a systematic thoracic CT scan. *Crit Care* [Internet] 2015 [cited 2023 Oct 19];19:366. Available from: [tps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608327/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608327/)



94. Prasetya IB, Cucunawangsih, Lorens JO, Sungono V, El-Khobar KE, Wijaya RS. Prognostic value of inflammatory markers in patients with COVID-19 in Indonesia. Clin Epidemiol Glob Health [Internet] 2021 [cited 2023 Oct 19];11:100803. Available from: <https://www.sciencedirect.com/science/article/pii/S2213398421001111>
95. Zulkifli K. Correlation Value Of Procalcitonin With Mortality Rate In Patients With Ventilator Associated Pneumonia Treated In The Intensive Care Unit Of Dr. Moh Hoesin Hospital Palembang Abstract. Anesth Crit Care 2017;35.
96. Liu D, Su L, Guan W, Xiao K, Xie L. Prognostic value of procalcitonin in pneumonia: A systematic review and meta-analysis. Respirol Carlton Vic 2016;21(2):280–8.



LAMPIRAN 1



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed, PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 503/UN4.6.4.5.31/ PP36/ 2023

Tanggal: 24 Juli 2023

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH23070452	No Sponsor	
Peneliti Utama	dr. Irma Rahayu, M. Biomed	Sponsor	
Judul Peneliti	Kadar Prokalsitonin, Protein C-Reaktif, dan Rasio Neutrofil Limfosit sebagai Prediktor Keparahan dan Luaran Pasien Pneumonia Komunitas		
No Versi Protokol	1	Tanggal Versi	4 Juni 2023
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	☐ Exempted ☒ Expedited ☐ Fullboard Tanggal	Masa Berlaku 24 Juli 2023 sampai 24 Juli 2024	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



LAMPIRAN 2

KEMENTERIAN KESEHATAN REPUBLIK INDONESIA
DIREKTORAT JENDERAL PELAYANAN KESEHATAN
 RUMAH SAKIT UMUM PUSAT DR. WAHIDIN SUDIROHUSODO
 Jalan Perintis Kemerdekaan Km. 11 Tamalanrea, Makassar, Kode Pos 90245
 Telp. (0411) 584675 – 581818 (*Hunting*), Fax. (0411) 587676
 Laman : www.rsupwahidin.com Surat Elektronik : tj@rsupwahidin.com

Nomor : DP.04.03/D.XIX.2/18608/2023 29 September 2023
 Hal : Izin Penelitian

Yth. Ketua Program Studi Pulmonologi dan Kedokteran Respirasi
Fakultas Kedokteran Universitas Hasanuddin

Sehubungan dengan surat saudara nomor **17695/UN.4.6.8/PT.01.04/2023**, tertanggal **27 Juli 2023**, hal **Pemohonan Izin Penelitian**, dapat kami fasilitasi dan memberikan izin pelaksanaan penelitian kepada:

Nama : **dr. Irma Rahayu**
 NIM : **C185192002**
 Prog. Pend. : **PPDS Pulmonologi dan Kedokteran Respirasi**
 No. HP : **082293327880**
 Judul : **Kadar Prokalsitonin, Protein C-Reaktif Dan Rasio Neutrofil Limfosit Sebagai Prediktor Keparahan Dan Luaran Pasien Pneumonia Komunitas di RSUP Dr. Wahidin Sudirohusodo Makassar**
 Jangka Waktu : **Tiga Bulan Setelah Surat ini di Keluarkan**
 Lokasi : **Instalasi Sistem Informasi Rumah Sakit**

dengan ketentuan sebagai berikut :

1. Mengikuti seluruh peraturan dan ketentuan penelitian yang berlaku di lingkup RSUP Dr Wahidin Sudirohusodo
2. Sebelum meneliti, peneliti wajib melapor kepada Pengawas Penelitian di masing-masing unit yang menjadi lokasi penelitian dan mengikuti syarat administrasi di *Clinical Research Unit* (CRU)
3. Pelaksanaan penelitian tidak mengganggu proses pelayanan, dan mendukung upaya peningkatan mutu pelayanan serta keselamatan pasien
4. Pemeriksaan penunjang, Bahan Habis Pakai (BHP) dan lain-lain yang digunakan dalam penelitian, menjadi tanggung jawab peneliti, tidak dibebankan kepada pasien ataupun RS
5. Peneliti melaporkan proses penelitian secara periodik serta hasil penelitian di akhir waktu penelitian di link <https://s.id/SisterEli>
6. Mencantumkan nama RSUP Dr Wahidin Sudirohusodo sebagai afiliasi institusi dalam naskah dan publikasi penelitian
7. Surat Keterangan Selesai Penelitian menjadi salah satu syarat untuk mengikuti Seminar Hasil Penelitian
8. Bukti Penyerahan Skripsi/Thesis/Disertasi ke RSUP Dr Wahidin Sudirohusodo menjadi syarat penyelesaian studi

Mohon dapat dipastikan agar ketentuan tersebut dipenuhi peneliti sebelum menyelesaikan studi di institusi saudara. Atas perhatian dan kerjasama yang baik, diucapkan terima kasih.

a.n. Direktur Utama
 Direktur SDM, Pendidikan dan Penelitian,



Dr. dr. Nu'man AS Daud, Sp.PD, K-GEH, FINASIM
 NIP197112142000031004

Tembusan:
 1 Kepala Instalasi Sistem Informasi Rumah Sakit



LAMPIRAN 3



KEMENTERIAN KESEHATAN REPUBLIK INDONESIA
DIREKTORAT JENDERAL PELAYANAN KESEHATAN
 RUMAH SAKIT UMUM PUSAT DR. WAHIDIN SUDIROHUSODO
 Jalan Perintis Kemerdekaan Km. 11 Tamalanrea, Makassar, Kode Pos 90245
 Telp. (0411) 584675 – 581818 (*Hunting*), Fax. (0411) 587676
 Laman : www.rsupwahidin.com Surat Elektronik : ju@rsupwahidin.com



Nomor : DP.04.03/D.XIX.2.2.2/257/2023

02 Oktober 2023

Hal : Pengantar Izin Penelitian

Yth. Kepala Instalasi Sistem Informasi Rumah Sakit

Berdasarkan Surat Izin Penelitian Nomor **DP.04.03/D.XIX.2/18608/2023** Tertanggal **29 September 2023**, dengan ini kami hadapkan Mahasiswa sbb :

Nama :	dr. Irma Rahayu
NIM :	C185192002
Prog. Pend. :	PPDS Pulmonologi dan Kedokteran Respirasi
No. HP :	082293327680
Judul :	Kadar Prokalsitonin, Protein C-Reaktif Dan Rasio Neutrofil Limfosit Sebagai Prediktor Keparahan Dan Luaran Pasien Pneumonia Komunitas di RSUP Dr. Wahidin Sudirohusodo Makassar
Jangka Waktu :	02 Oktober 2023 s.d 02 Januari 2024

Agar dapat difasilitasi dan dibantu proses pengambilan data sesuai subyek/metode dan metode yang telah disepakati, Pemantauan pelaksanaan penelitian adalah kewenangan Kepala Instalasi/Sub Instalasi sebagai Pengawas Penelitian. Jika terdapat penyimpangan dalam proses penelitian yang berdampak pada mutu pelayanan dan keselamatan pasien, Kepala Instalasi/Sub Instalasi sebagai Pengawas Penelitian dapat menghentikan sementara penelitian, dan dilaporkan ke Sub Substansi Penelitian dan Pengembangan untuk diproses lebih lanjut.

a.n. Koordinator Pendidikan dan Penelitian,
 Sub Koordinator Penelitian dan Pengembangan,



Dewi Rizki Nurmala, SKM, M.Kes
 NIP198101132005022004

